Peter MacCallum Cancer Centre, Australia
113
26
43
33
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.0%
9 terminated/withdrawn out of 113 trials
78.6%
-7.9% vs industry average
8%
9 trials in Phase 3/4
12%
4 of 33 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (113)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Role: collaborator
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Role: lead
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Role: collaborator
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
Role: lead
EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET
Role: lead
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
Role: lead
Novel Treatment of Radiation Associated Dysphagia With Statins
Role: lead
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
Role: lead
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Role: lead
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
Role: lead
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
Role: lead
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
Role: collaborator
Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever
Role: lead
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Role: collaborator
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
Role: collaborator
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Role: collaborator
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
Role: lead
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
Role: lead
Implementing Surgery School Prehabilitation Using Telehealth
Role: collaborator
Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial
Role: lead